Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma

Hottinger, A F; Ben Aissa, Assma; Espeli, Vittoria; Squiban, D; Dunkel, Nathalie; Vargas Gomez, Maria Isabel; Hundsberger, T; Mach, Nicolas; Schaller, Karl Lothard; Weber, D C; Bodmer, A; Dietrich, Pierre-Yves

doi:10.1038/bjc.2014.209

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma
Authors		Hottinger, A F Ben Aissa, Assma Espeli, Vittoria Squiban, D Dunkel, Nathalie Vargas Gomez, Maria Isabel Hundsberger, T Mach, Nicolas Schaller, Karl Lothard Weber, D C Bodmer, A Dietrich, Pierre-Yves show all authors [1 - 12]
Published in		British journal of cancer. 2014, vol. 110, no. 11, p. 2655-2661
Abstract		Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase. This phase I open-label, noncontrolled dose escalation study was performed to determine the safety and maximum tolerated dose (MTD) of Sb in combination with radiation therapy (RT) and temozolomide (TMZ) in 17 patients with newly diagnosed high-grade glioma.
Keywords		Adult — Aged — Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics/therapeutic use/toxicity — Brain Neoplasms/mortality/therapy — Chemoradiotherapy — Dacarbazine/administration & dosage/analogs & derivatives — Disease-Free Survival — Female — Glioblastoma/mortality/therapy — Humans — Male — Maximum Tolerated Dose — Middle Aged — Niacinamide/administration & dosage/analogs & derivatives — Phenylurea Compounds/administration & dosage — Treatment Outcome
Identifiers		DOI: 10.1038/bjc.2014.209 PMID: 24786603
Full text		Article (Published version) (462 Kb) - Free access Erratum (48 Kb) - Free access
Structures		Faculté de médecine / Section de médecine clinique / Département de médecine Faculté de médecine / Section de médecine clinique / Département des neurosciences cliniques Faculté de médecine / Section de médecine clinique / Département de radiologie et informatique médicale
Research groups		Groupe Schaller Karl Lothard (neurochirurgie) (851) Immunothérapie des cancers (42) Traits génétiques complexes (901)
Citation (ISO format)		HOTTINGER, A F et al. Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma. In: British journal of cancer, 2014, vol. 110, n° 11, p. 2655-2661. doi: 10.1038/bjc.2014.209 https://archive-ouverte.unige.ch/unige:90881